- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04081805
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2) (EPMLARF)
LASER and Radiofrequency as Alternative Treatment of Vaginal Vulvar Atrophy in Women Treated for Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Women treated for breast cancer with moderate or severe signs or symptoms of vulvovaginal atrophy will be eligible for the study.
The patients will be randomized to receive one of the three intravaginal therapies: LASER, Micro Ablative radiofrequency or Promestriene. The applications will occur in the interval of 30 days for 3 times, for LASER and Radiofrequency groups. For the promestriene group, the application will be done by the patient, daily for 2 weeks and then twice a week for 3 months, and each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube, to verify the correct use.
The follow-up visits will occur 30, 90, 180 and 360 days after the conclusion of the third month of treatment.
Will be evaluated: vulvar and vaginal histology before and after the use of LASER, radiofrequency or estriol; microbiota and vaginal pH before and after the use of LASER, radiofrequency or promestriene; extracellular matrix and metalloproteinases in the remodeling of vulvovaginal collagen induced by promestriene, LASER and radiofrequency; quality of life, sexual dysfunctions and complains before and after the use of LASER, radiofrequency or hormones; metabolomics and vaginal microbiome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ana Maria HM Bianchi-Ferraro, PhD
- Phone Number: +5511995217431
- Email: anamariahmb@yahoo.com.br
Study Contact Backup
- Name: Zsuzsanna IK Jarmy-di Bella, PhD
- Phone Number: 5511983490033
- Email: zsuvi@uol.com.br
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 0-4023- 062
- Recruiting
- Federal University of Sao Paulo - Unifesp
-
Contact:
- Ana Maria HM Bianchi-Ferraro, PhD
- Phone Number: +5511995217431
- Email: anamariahmb@yahoo.com.br
-
Contact:
- Zsuzsanna IK Jarmy-di Bella, PhD
- Phone Number: +5511983490033
- Email: zsuvi@uol.com.br
-
Sub-Investigator:
- Marair FG Sartori, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women with breast cancer treated with surgery and / or chemotherapy and / or radiotherapy, that has been concluded at least 6 months before inclusion, whether or not using aromatase inhibitor and complaining of vulvovaginal atrophy
To present, at least moderate, or severe intensity (score 4 or more of visual analog scale ( 0-10)) of one of the signs or symptoms of vulvovaginal atrophy:
- Burning
- Discomfort
- Dryness
- Cracks
- Pruritus
- Lack of vaginal lubrication
- Penetration dyspareunia that began at the menopausal or postmenopausal transition
- Decreased vaginal epithelium turgor and trophism
- Deletion of mucous and skin folds.
- Absence of vaginal surgical procedure in the last year
- Genital prolapse stage no greater than stage II of Pelvic Organs Prolapse Quantitation (POP-Q) with Ba, Bp or C points less than or equal to 0
Exclusion Criteria:
- Active genital infection
- Active infection of HPV (human papillomavirus) or Herpes
- users of medications with estrogenic effect (digoxin and other chemicals)
- Postmenopausal genital bleeding
- uncontrolled diabetes
- use of multivitamins with zinc
- use of copper or hormonal IUDs (intrauterine device) at the time of inclusion
- presence of genitourinary or rectovaginal fistulas
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LASER
The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy.
The applications will be separated by the interval of 30 days
|
The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months .
Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar
application of LASER, to postmenopausal genitourinary syndrome.
The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
Other Names:
|
Active Comparator: Micro Ablative Radiofrequency
The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy.
The applications will be separated by the interval of 30 days
|
Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome.
The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
Other Names:
|
Active Comparator: Promestriene
The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months .
Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
|
The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Improvement of signs and symptoms of vulvovaginal atrophy with intravaginal LASER, Micro Ablative Radiofrequency, and topic promestriene
Time Frame: The evaluation will be done 90 days after treatment]
|
Will be applied a Visual Analogic Scale (0-10) to access the improvement of genitourinary signs and symptoms, the results of the three groups will be compared
|
The evaluation will be done 90 days after treatment]
|
Satisfaction with treatment by intravaginal LASER, Micro ablative Radiofrequency, and topic promestriene for women treated for breast cancer, with genitourinary atrophy syndrome
Time Frame: The evaluation will be done 90 days after treatment
|
Will be applied a LIKERT Satisfaction Scale (1-5) to access the satisfaction with the treatment, the results of the three groups will be compared
|
The evaluation will be done 90 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Microbiota before and after the use of intravaginal LASER, Micro Ablative radiofrequency or topic promestriene
Time Frame: The evaluation will occur pre-treatment 30, 90 , 180 and 360 days after treatment]
|
The vaginal flora will be evaluated by vaginal smear.
The results of the three groups will be compared
|
The evaluation will occur pre-treatment 30, 90 , 180 and 360 days after treatment]
|
Evaluation of vaginal pH before and after the use of intravaginal LASER, Micro ablative radiofrequency or topic promestriene
Time Frame: The evaluation will occur pre-treatment and 30, 90, 180 and 360 days after treatment
|
The vaginal pH will be verified by the use of pH tape's.
The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30, 90, 180 and 360 days after treatment
|
Histologic evaluation of vagina and vulva before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The evaluation will occur pre-treatment and 30 and 180 days after treatment
|
Thickness of epithelium (mm and number of layers), and evaluation of expression of Ki-67 and VEGF (vascular endothelial growth factor) will be done on vaginal and vulvar biopsies, in order to evaluate the tissue regeneration ( a greater the number of layers associated with the expression of VEGF and ki67 indicate a tissue regeneration, the combination of this measures, and not evaluation each one isolated, are important to evaluate histological improvement).
The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30 and 180 days after treatment
|
Evaluation of impact in Quality of life after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The evaluation will occur pre-treatment and 30 and 180 and 360 days after treatment]
|
The IQol (incontinence quality of life questionnaire, validated to portuguese language - score 0-100) will be used to evaluate quality of life .The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30 and 180 and 360 days after treatment]
|
Evaluation of impact in Sexual function after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The evaluation will occur pre-treatment and 30 180 and 360 days after treatment
|
The FSF-I (Female Sexual Function Index , validated to portuguese language- score range from 2 - 36) will be used to evaluate sexual function .
The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30 180 and 360 days after treatment
|
Evaluation of extracellular matrix before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The evaluation will occur pre-treatment and 30 and 180 days after treatment]
|
Evaluation of the composition and concentration of the glycosaminoglycans of extracellular matrix in the vaginal and vulvar biopsies by specific markers.
The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30 and 180 days after treatment]
|
Evaluation of matrix metalloproteinases(MMP) in remodeling of vulvovaginal collagen induced by intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The evaluation will occur pre-treatment and 30 and 180 days after treatment
|
Evaluation of the tissue distribution of the MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 metalloproteinases of collagen I, II, IV and elastin proteins by specific markers on vaginal and vulvar biopsies.
The results of the three groups will be compared
|
The evaluation will occur pre-treatment and 30 and 180 days after treatment
|
Evaluation of visual aspect of vulva after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic promestriene.
Time Frame: The pictures will be taken before and 30 days and 180 days after treatment.]
|
Pictures of vulva will be taken before and after treatment.
The images will be evaluated by a blind gynecologist and dermatologist regarding the type of treatment and the chronological order of the photos, which will classify the images as: better; equal or worse, in relation to tropism and number of vulvar skin grooves, The results of the three groups will be compared
|
The pictures will be taken before and 30 days and 180 days after treatment.]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Zsuzsanna IK Jarmy-di Bella, PhD, Professor
- Study Director: Marair GF Sartori, PhD, Professor and Head of Gynecology Department
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP0431/2018 arm 2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on LASER
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
University of Sao Paulo General HospitalCompletedOsteoarthritisBrazil
-
State University of Minas GeraisFundação de Amparo à Pesquisa do estado de Minas GeraisActive, not recruiting
-
Mashhad University of Medical SciencesUnknownTemporomandibular Joint Disorder
-
Universidade Norte do ParanáUniversidade Estadual de LondrinaCompletedPerformance | Aged | Muscle Strength | Resistance Training | LasersBrazil
-
Northwestern UniversityEnrolling by invitation
-
Universidade Estadual Paulista Júlio de Mesquita...Completed
-
Montefiore Medical CenterNot yet recruitingHidradenitis Suppurativa | ScarringUnited States
-
Federal University of Health Science of Porto AlegreUnknown
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation Trust; University of Southern Denmark; Yamagata University and other collaboratorsCompletedProliferative Diabetic RetinopathyDenmark